Aberdeen Group plc Has $34.15 Million Stake in Edwards Lifesciences Corporation $EW

Key Points

• Aberdeen Group plc has reduced its stock holdings in Edwards Lifesciences Corporation by 56.4%, now owning approximately 0.08% of the company worth $34.15 million.
• Despite Aberdeen's reduction, other hedge funds like Dimensional Fund Advisors and Horizon Investments increased their positions, indicating mixed sentiment among institutional investors.
• Wall Street analysts are optimistic about Edwards Lifesciences, with a consensus rating of "Moderate Buy" and a price target increase from various firms, reflecting growth expectations for the company's stock.

Aberdeen Group plc lowered its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 56.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 474,303 shares of the medical research company's stock after selling 614,049 shares during the period. Aberdeen Group plc owned approximately 0.08% of Edwards Lifesciences worth $34,150,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the business. Prosperity Consulting Group LLC boosted its stake in Edwards Lifesciences by 3.6% in the 4th quarter. Prosperity Consulting Group LLC now owns 3,906 shares of the medical research company's stock worth $289,000 after purchasing an additional 134 shares in the last quarter. Arlington Trust Co LLC raised its stake in Edwards Lifesciences by 1.2% in the 1st quarter. Arlington Trust Co LLC now owns 11,092 shares of the medical research company's stock valued at $804,000 after purchasing an additional 135 shares during the last quarter. Valeo Financial Advisors LLC boosted its position in shares of Edwards Lifesciences by 2.8% during the 1st quarter. Valeo Financial Advisors LLC now owns 5,136 shares of the medical research company's stock valued at $372,000 after acquiring an additional 142 shares during the last quarter. Versant Capital Management Inc increased its position in shares of Edwards Lifesciences by 9.3% during the 1st quarter. Versant Capital Management Inc now owns 1,698 shares of the medical research company's stock worth $123,000 after purchasing an additional 145 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its holdings in Edwards Lifesciences by 0.5% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company's stock valued at $2,170,000 after acquiring an additional 145 shares during the period. Hedge funds and other institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Price Performance

NYSE:EW traded down $0.4870 during trading hours on Friday, reaching $80.6730. The company had a trading volume of 1,025,651 shares, compared to its average volume of 4,505,574. Edwards Lifesciences Corporation has a one year low of $64.00 and a one year high of $83.00. The stock has a 50-day moving average of $77.45 and a two-hundred day moving average of $74.60. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $47.36 billion, a PE ratio of 11.61, a PEG ratio of 3.93 and a beta of 1.08.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, topping analysts' consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The business had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. During the same period in the prior year, the company earned $0.70 EPS. Edwards Lifesciences's revenue for the quarter was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages recently weighed in on EW. Dbs Bank upgraded shares of Edwards Lifesciences to a "hold" rating in a research note on Monday, June 2nd. Wells Fargo & Company upped their price target on shares of Edwards Lifesciences from $84.00 to $88.00 and gave the company an "overweight" rating in a report on Thursday, August 7th. William Blair upgraded Edwards Lifesciences to a "strong-buy" rating in a report on Friday, July 25th. Daiwa America raised shares of Edwards Lifesciences from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, July 29th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the company a "neutral" rating in a research report on Friday, July 25th. Three analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $85.90.

Insider Activity at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 2,570 shares of the stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $77.40, for a total value of $198,918.00. Following the sale, the vice president directly owned 50,356 shares in the company, valued at $3,897,554.40. This trade represents a 4.86% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Daniel J. Lippis sold 4,114 shares of the business's stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $79.46, for a total value of $326,898.44. Following the completion of the transaction, the vice president directly owned 22,002 shares of the company's stock, valued at approximately $1,748,278.92. The trade was a 15.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 24,584 shares of company stock worth $1,897,762. 1.29% of the stock is owned by insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.